Edward C. Li

758 total citations
22 papers, 605 citations indexed

About

Edward C. Li is a scholar working on Economics and Econometrics, Immunology and Oncology. According to data from OpenAlex, Edward C. Li has authored 22 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 8 papers in Immunology and 7 papers in Oncology. Recurrent topics in Edward C. Li's work include Biosimilars and Bioanalytical Methods (8 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Pharmaceutical Economics and Policy (7 papers). Edward C. Li is often cited by papers focused on Biosimilars and Bioanalytical Methods (8 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Pharmaceutical Economics and Policy (7 papers). Edward C. Li collaborates with scholars based in United States. Edward C. Li's co-authors include Lisa E. Davis, Glen T. Schumock, Linda M. Matusiak, Robert J. Hunkler, Lee C. Vermeulen, Katie J. Suda, JoAnn Stubbings, Michelle D. Wiest, James M. Hoffman and Shannon D. Scott and has published in prestigious journals such as Journal of Clinical Oncology, Drug Discovery Today and Clinical Therapeutics.

In The Last Decade

Edward C. Li

21 papers receiving 574 citations

Peers

Edward C. Li
Ylenia Ingrasciotta Italy
Eric M. Tichy United States
Hye-Young Kang South Korea
Karl Matuszewski United States
James Chan United States
Frank Xiaoqing Liu United States
Jetty A. Overbeek Netherlands
Andrea Belisari Italy
Mona Aeysha Khalid United Kingdom
N. Muszbek United Kingdom
Ylenia Ingrasciotta Italy
Edward C. Li
Citations per year, relative to Edward C. Li Edward C. Li (= 1×) peers Ylenia Ingrasciotta

Countries citing papers authored by Edward C. Li

Since Specialization
Citations

This map shows the geographic impact of Edward C. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward C. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward C. Li more than expected).

Fields of papers citing papers by Edward C. Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward C. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward C. Li. The network helps show where Edward C. Li may publish in the future.

Co-authorship network of co-authors of Edward C. Li

This figure shows the co-authorship network connecting the top 25 collaborators of Edward C. Li. A scholar is included among the top collaborators of Edward C. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward C. Li. Edward C. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Edward C., et al.. (2021). Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.. Journal of Clinical Oncology. 39(28_suppl). 58–58. 1 indexed citations
3.
4.
5.
Schumock, Glen T., JoAnn Stubbings, Michelle D. Wiest, et al.. (2018). National trends in prescription drug expenditures and projections for 2018. American Journal of Health-System Pharmacy. 75(14). 1023–1038. 28 indexed citations
6.
Li, Edward C., et al.. (2018). Spending on Antineoplastic Agents in the United States, 2011 to 2016. Journal of Oncology Practice. 14(11). e683–e691. 11 indexed citations
7.
Li, Edward C., Glen T. Schumock, & Samuel L. Hong. (2017). Spending on antineoplastic agents in the United States: 2011-2016.. Journal of Clinical Oncology. 35(15_suppl). 6618–6618. 1 indexed citations
8.
Schumock, Glen T., Edward C. Li, Michelle D. Wiest, et al.. (2017). National trends in prescription drug expenditures and projections for 2017. American Journal of Health-System Pharmacy. 74(15). 1158–1173. 42 indexed citations
9.
Schumock, Glen T., Edward C. Li, Katie J. Suda, et al.. (2016). National trends in prescription drug expenditures and projections for 2016. American Journal of Health-System Pharmacy. 73(14). 1058–1075. 80 indexed citations
10.
Li, Edward C., Richat Abbas, Ira Jacobs, & Donghua Yin. (2015). Considerations in the early development of biosimilar products. Drug Discovery Today. 20. 1–9. 23 indexed citations
11.
Schumock, Glen T., Edward C. Li, Katie J. Suda, et al.. (2015). National trends in prescription drug expenditures and projections for 2015. American Journal of Health-System Pharmacy. 72(9). 717–736. 31 indexed citations
12.
Vermeulen, Lee C., James M. Hoffman, Nilay D. Shah, et al.. (2015). Accuracy of annual prescription drug expenditure forecasts inAJHP. American Journal of Health-System Pharmacy. 72(19). 1642–1648. 7 indexed citations
13.
Schumock, Glen T., Edward C. Li, Katie J. Suda, et al.. (2014). National trends in prescription drug expenditures and projections for 2014. American Journal of Health-System Pharmacy. 71(6). 482–499. 59 indexed citations
14.
15.
Zelenetz, Andrew D., Edward L. Braud, Barry D. Dickinson, et al.. (2011). NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. Journal of the National Comprehensive Cancer Network. 9(Suppl_4). S–1. 111 indexed citations
16.
Li, Edward C., et al.. (2010). Drug‐Induced QT‐Interval Prolongation: Considerations for Clinicians. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(7). 684–701. 56 indexed citations
17.
Johnson, Philip E., Rekha Garg, Scott Gottlieb, et al.. (2010). NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders. Journal of the National Comprehensive Cancer Network. 8(Suppl_7). S–7. 17 indexed citations
18.
Li, Edward C. & Jessica K. DeMartino. (2010). Preliminary Report: The Development of the NCCN Comparative Therapeutic Index™ as a Clinical Evaluative Process for Existing Data in Oncology. Journal of the National Comprehensive Cancer Network. 8(Suppl_5). S–1. 6 indexed citations
19.
Li, Edward C., et al.. (2010). Insights and Perspectives in the Clinical and Operational Management of Cancer-Related Anemia. Journal of the National Comprehensive Cancer Network. 8(Suppl_7). S–38. 3 indexed citations
20.
Li, Edward C. & Lisa E. Davis. (2003). Zoledronic acid: A new parenteral bisphosphonate. Clinical Therapeutics. 25(11). 2669–2708. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ylenia Ingrasciotta Breakdown of academic impact, for papers by Eric M. Tichy Breakdown of academic impact, for papers by Hye-Young Kang Breakdown of academic impact, for papers by Karl Matuszewski Breakdown of academic impact, for papers by James Chan Breakdown of academic impact, for papers by Frank Xiaoqing Liu Breakdown of academic impact, for papers by Jetty A. Overbeek Breakdown of academic impact, for papers by Andrea Belisari Breakdown of academic impact, for papers by Mona Aeysha Khalid Breakdown of academic impact, for papers by N. Muszbek
Rankless by CCL
2026